CA3136081A1 - Compositions comprising indigo and/or an indigo derivative and methods of use thereof - Google Patents

Compositions comprising indigo and/or an indigo derivative and methods of use thereof Download PDF

Info

Publication number
CA3136081A1
CA3136081A1 CA3136081A CA3136081A CA3136081A1 CA 3136081 A1 CA3136081 A1 CA 3136081A1 CA 3136081 A CA3136081 A CA 3136081A CA 3136081 A CA3136081 A CA 3136081A CA 3136081 A1 CA3136081 A1 CA 3136081A1
Authority
CA
Canada
Prior art keywords
indirubin
dosage form
indigo
dispersion
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3136081A
Other languages
English (en)
French (fr)
Inventor
Matthew Davidson
Julie SAIKI
Johan ANDREASSON
Michael David FAVERO
Matthew Benjamin Greene
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azora Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3136081A1 publication Critical patent/CA3136081A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3136081A 2019-05-03 2020-05-01 Compositions comprising indigo and/or an indigo derivative and methods of use thereof Pending CA3136081A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962843184P 2019-05-03 2019-05-03
US62/843,184 2019-05-03
PCT/US2020/031174 WO2020227151A1 (en) 2019-05-03 2020-05-01 Compositions comprising indigo and/or an indigo derivative and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3136081A1 true CA3136081A1 (en) 2020-11-12

Family

ID=70775588

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3136081A Pending CA3136081A1 (en) 2019-05-03 2020-05-01 Compositions comprising indigo and/or an indigo derivative and methods of use thereof

Country Status (10)

Country Link
US (3) US20200345645A1 (cg-RX-API-DMAC7.html)
EP (1) EP3962458A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022531012A (cg-RX-API-DMAC7.html)
KR (1) KR20220044435A (cg-RX-API-DMAC7.html)
CN (1) CN114340600A (cg-RX-API-DMAC7.html)
AU (1) AU2020269379A1 (cg-RX-API-DMAC7.html)
CA (1) CA3136081A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021013386A (cg-RX-API-DMAC7.html)
TW (1) TW202106296A (cg-RX-API-DMAC7.html)
WO (1) WO2020227151A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
TWI836752B (zh) 2021-11-30 2024-03-21 美商安督奎斯特機器人公司 用於機器人控制醫療裝置的力傳輸系統
WO2023170714A1 (en) * 2022-03-10 2023-09-14 Joy Vadakkan Thomas A topical herbal composition for fungal infection, scaling, foot cracking, eczema and dry skin diseases
KR20250069676A (ko) * 2022-10-10 2025-05-19 더데르마 상하이 컴퍼니 리미티드 궤양 예방 및/또는 치료를 위한 스틸벤 유도체의 용도
WO2025008784A1 (en) * 2023-07-04 2025-01-09 Glenmark Life Sciences Limited Solid dispersions of tapinarof and a process for the preparation thereof
CN121337758A (zh) * 2025-11-26 2026-01-16 河北省中医院(河北中医药大学第一附属医院、河北省青少年儿童脊柱侧弯防控中心) 一种可降解的肠道药物靶向释放胶囊及制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US7582670B2 (en) * 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
JP2013103899A (ja) * 2011-11-11 2013-05-30 Fuji Chem Ind Co Ltd 難溶性薬物の新規な固体分散体
JP6382187B2 (ja) * 2012-06-21 2018-08-29 フォスフォレックス,インコーポレーテッド インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
TWI615157B (zh) * 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
JP2017500343A (ja) * 2013-12-20 2017-01-05 フォスフォレックス,インコーポレーテッド インジルビン固体分散体組成物
TWI737602B (zh) 2015-04-09 2021-09-01 瑞士商高德美公司 藥學組合物及其製劑
CA3021071A1 (en) * 2016-04-19 2017-10-26 Ferring B.V. Oral pharmaceutical compositions of mesalazine
WO2019142799A1 (ja) * 2018-01-18 2019-07-25 学校法人慶應義塾 潰瘍性大腸炎治療カプセル剤

Also Published As

Publication number Publication date
KR20220044435A (ko) 2022-04-08
JP2022531012A (ja) 2022-07-05
US20250255820A1 (en) 2025-08-14
MX2021013386A (es) 2022-03-22
TW202106296A (zh) 2021-02-16
CN114340600A (zh) 2022-04-12
EP3962458A1 (en) 2022-03-09
WO2020227151A1 (en) 2020-11-12
US20220249382A1 (en) 2022-08-11
US20200345645A1 (en) 2020-11-05
AU2020269379A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
US20250255820A1 (en) Compositions comprising indigo and/or an indigo derivative and methods of use thereof
US11173123B2 (en) Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
US5415871A (en) Therapeutic agents
EP3923914B1 (en) Afabicin formulation, method for making the same
MX2011004395A (es) Composiciones farmaceuticas que contienen diacereina.
US20090258947A1 (en) Novel low dose pharmaceutical compositions comprising nimesulide, preparation and use thereof
GB2414668A (en) Sustained release delivery system for tetracycline compounds
US20200345691A1 (en) Compositions comprising indigo and/or an indigo derivative and methods of use thereof
WO2022138717A1 (ja) 経口固形製剤
WO2005065662A1 (en) Solid dosage formulations of galantamine
RS66829B1 (sr) Kompozicija furazidina sa produženim oslobađanjem
HK40063531A (en) Afabicin formulation, method for making the same
HK40063531B (en) Afabicin formulation, method for making the same
KR0184350B1 (ko) 오메프라졸 구강점막 부착 정제 조성물
EA045511B1 (ru) Состав с афабицином, способ его получения и его применение
Deshpande Formulation and in vitro Evaluation of Bilayered Tablets of Metformin Hydrochloride and Atorvastatin Calcium
TW201726124A (zh) 二氟甲基鳥氨酸及舒林酸(sulindac),固定劑量組合調配物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220927

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240903

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251016

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251216